Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Group 1 - Vaxcyte Incorporated (NASDAQ:PCVX) is identified as one of the 17 biotechnology stocks with more than 50% upside potential [1] - Cantor Fitzgerald maintains an Overweight rating on Vaxcyte, noting progress in its clinical pipeline, with the Phase 3 OPUS-1 trial topline readout expected in Q4 2026 and a BLA filing planned for the following year [1] - Needham analyst Joseph Stringer raised the price target for Vaxcyte from $90 to $110, indicating over 100% upside at current levels [3] Group 2 - Stringer's rating is supported by Vaxcyte's inclusion on Needham's Conviction List as a Top Pick for 2026, following positive Phase 2 data for VAX-31, which reduces risk ahead of the Phase 3 readout [4] - Vaxcyte is focused on developing next-generation vaccines for serious bacterial diseases, utilizing innovative synthetic methods and advanced chemistry to create complex, high-fidelity vaccines [5]